CNMDCONMED Corporation

Recently, CONMED Corporation was highlighted for its positioning in differentiated surgical platforms such as AirSeal, Buffalo Filter, and BioBrace, with these products benefiting from supportive regulatory trends and growing clinical adoption, while the company continues to face risks from tariffs and slower expansion in specific platforms like AirSeal. An interesting angle is that regulatory momentum around operating room air quality and clinician willingness to adopt newer biomaterials...

What Is Driving Fresh Interest In CONMED Stock Today CONMED (CNMD) is back in focus as investors assess the adoption of its AirSeal, Buffalo Filter, and BioBrace platforms, along with tariff headwinds and slower AirSeal growth, in the context of the company’s broader earnings profile. See our latest analysis for CONMED. CONMED’s share price has moved to US$49.25 after a strong 30 day share price return of 14% and a 90 day share price return of 36.12%. However, the 1 year total shareholder...

CNMD's 16% monthly rally is backed by stronger growth, margin gains and raised earnings guidance, but cash-flow and execution risks remain.

CNMD's low valuation and improved earnings outlook strengthen its appeal, but cash-flow pressure and execution risks keep the buy case measured.

CONMED raised its 2026 adjusted EPS outlook after a strong second quarter, but slower organic growth and higher financing costs keep the setup mixed.

CONMED's growth outlook is supported by Buffalo Filter, BioBrace and organic momentum, though slower AirSeal growth and tariffs remain key risks.

Stryker has gained 3.8% since March-end as Mako robotics, hospital capital demand and international growth drive momentum.

Check out the companies making headlines this week:

Shares of medical tech company CONMED (NYSE:CNMD) jumped 10.5% in the afternoon session after the company reported second-quarter adjusted earnings that beat analyst expectations and raised its full-year guidance.

CNMD's Q2 earnings and revenues beat estimates, while margin growth and solid international sales support a higher 2026 EPS outlook.

CONMED (NYSE:CNMD) reported second-quarter 2026 net sales of $343.5 million, up 0.3% on a reported basis but down 0.5% in constant currency. Organic sales, which exclude the company’s exited gastroenterology product offerings, rose 6% year over year and modestly exceeded management’s expectations.

The headline numbers for Conmed (CNMD) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Conmed (CNMD) delivered earnings and revenue surprises of +25.46% and +1.85%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Medical tech company CONMED (NYSE:CNMD) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, but sales were flat year on year at $343.5 million. The company expects the full year’s revenue to be around $1.37 billion, close to analysts’ estimates. Its non-GAAP profit of $1.38 per share was 24.3% above analysts’ consensus estimates.

Medical tech company CONMED (NYSE:CNMD) will be reporting results this Wednesday after market close. Here’s what investors should know.

Conference spotlight and why CONMED stock is on watch CONMED (CNMD) is in focus as the company prepares for its presentation at the SRS Annual Meeting, where consultant urological surgeons Amit Taggar and Nikhil Vasdev are scheduled to speak on July 24, 2026. See our latest analysis for CONMED. Beyond the conference appearance, CONMED’s share price has recently picked up, with a 30 day share price return of 18.72% and a 90 day gain of 12.70%. However, the 1 year total shareholder return is...

CNMD's FDA-expanded AirSeal indication adds da Vinci 5 hex cannula compatibility, supporting broader use across Intuitive Surgical's robotic systems.

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.

Shares of medical tech company CONMED (NYSE:CNMD) jumped 9% in the afternoon session after reports revealed the company is exploring a potential sale.

Conmed stock rocketed closer to breakout territory Monday on reports the medtech company is exploring a possible sale.

Conmed stock jumped Monday following a report that the medical technology company is considering a sale.

Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 0.2% and

On Friday, a Bloomberg Law report indicated that the company is considering a sale after private equity investors expressed interest.